Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Spire Healthcare Group plc (SPI.L)
London, ENG, GB
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It operates in two segments: Hospitals Business and Primary Care. The company provides diagnostics, inpatient, day case, and outpatient care in areas, including orthopedics, gynaecology, cardiology, neurology, oncology, and general surgery; and primary care needs of outpatients, such as GP services, occupational health services, and mental and physical health services. It also offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, digestive and bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. In addition, the company provides eye surgery and treatments, family planning, gastroenterology, general medicine, haematology, hand surgery, hip and knee replacement treatment, and heart and kidney treatments. Further, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory medicine, and rheumatology; and scans and investigations, skin treatments, spinal neurosurgery, sports science, urology, vascular surgery, weight loss, and women's health. Additionally, the company provides treatments in the areas of breast enlargement, cataract removal surgery, gastric bypass surgery, and prostate surgery; and offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.61% | -0.90% | +35.58% | +8.87% | -3.70% | +32.34% | +8.33% | -0.90% | -9.80% | -36.97% | +69.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+4.5% Q4'25: +14.7% (vs Q4'23)
-
EPS growth Medical - Care Facilities: +19.2%-34.4% Q4'25: -31.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+4.7% ★ Q4'25: +11.2% (vs Q4'23)
-
EBIT margin Medical - Care Facilities: +11.3%+9.1% Q4'25: +8.6% (vs Q4'23)
-
ROIC Medical - Care Facilities: +6.8%+6.5% Q4'25: +13.3% (vs Q4'23)
-
Share dilution Medical - Care Facilities: +0.0%-1.5% ★ Q4'25: -3.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×5.01× Q4'25: 2.56× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
856.00M
est: 859.30M (-0.4%)
|
884.80M
est: 886.54M (-0.2%)
|
926.40M
est: 924.72M (+0.2%)
|
931.70M
est: 937.01M (-0.6%)
|
931.10M
est: 929.81M (+0.1%)
|
980.80M
est: 953.15M (+2.9%)
|
919.90M
est: 850.79M (+8.1%)
|
1.11B
est: 1.09B (+1.0%)
|
1.20B
est: 1.19B (+1.0%)
|
1.36B
est: 1.45B (-6.0%)
|
1.51B
est: 1.52B (-0.8%)
|
1.58B
est: 1.59B (-0.5%)
|
1.61B
1.57B – 1.65B
+1.3% YoY
|
1.70B
1.65B – 1.75B
+5.7% YoY
|
1.78B
1.78B – 1.78B
+4.9% YoY
|
1.82B
1.77B – 1.87B
+2.2% YoY
|
| EBITDA |
126.80M
est: 104.04M (+21.9%)
|
143.90M
est: -49.73M (+389.4%)
|
145.10M
est: 105.98M (+36.9%)
|
100.40M
est: 106.80M (-6.0%)
|
163.50M
est: 59.36M (+175.4%)
|
185.30M
est: 3.39M (+5,358.1%)
|
-51.90M
est: 14.34M (-461.9%)
|
182.20M
est: 16.11M (+1,030.8%)
|
193.30M
est: 19.77M (+877.8%)
|
231.20M
est: 245.36M (-5.8%)
|
250.40M
est: 258.33M (-3.1%)
|
262.50M
est: 269.57M (-2.6%)
|
273.20M
267.20M – 280.45M
+1.3% YoY
|
288.76M
279.35M – 296.47M
+5.7% YoY
|
302.80M
302.80M – 302.80M
+4.9% YoY
|
309.35M
300.86M – 317.58M
+2.2% YoY
|
| EBIT |
74.10M
est: 31.50M (+135.3%)
|
86.50M
est: 62.92M (+37.5%)
|
84.10M
est: 99.81M (-15.7%)
|
43.00M
est: 94.32M (-54.4%)
|
74.60M
est: 42.51M (+75.5%)
|
93.70M
est: 76.54M (+22.4%)
|
-145.90M
est: 77.51M (-288.2%)
|
85.90M
est: 87.08M (-1.4%)
|
95.40M
est: 106.85M (-10.7%)
|
127.60M
est: 158.33M (-19.4%)
|
138.20M
est: 166.69M (-17.1%)
|
142.90M
est: 173.95M (-17.8%)
|
176.29M
172.42M – 180.97M
+1.3% YoY
|
186.33M
180.26M – 191.31M
+5.7% YoY
|
195.39M
195.39M – 195.39M
+4.9% YoY
|
199.61M
194.14M – 204.93M
+2.2% YoY
|
| Net Income |
6.00M
est: 47.08M (-87.3%)
|
60.00M
est: 6.28M (+855.1%)
|
53.60M
est: 62.71M (-14.5%)
|
16.80M
est: 54.36M (-69.1%)
|
100.0K
est: 16.65M (-99.4%)
|
7.20M
est: 102.9K (+6,898.6%)
|
-233.90M
est: 5.97M (-4,018.6%)
|
-9.70M
est: 6.71M (-244.7%)
|
8.60M
est: 21.50M (-60.0%)
|
27.30M
est: 28.30M (-3.5%)
|
25.40M
est: 38.94M (-34.8%)
|
16.40M
est: 37.09M (-55.8%)
|
36.53M
24.95M – 42.19M
-1.5% YoY
|
64.71M
35.86M – 72.89M
+77.2% YoY
|
65.45M
60.07M – 70.83M
+1.1% YoY
|
76.97M
74.22M – 79.63M
+17.6% YoY
|
| SGA |
61.00M
est: 201.38M (-69.7%)
|
63.70M
est: 207.76M (-69.3%)
|
63.30M
est: 216.71M (-70.8%)
|
63.90M
est: 219.59M (-70.9%)
|
308.30M
est: 217.90M (+41.5%)
|
262.30M
est: 223.37M (+17.4%)
|
292.80M
est: 199.38M (+46.9%)
|
312.90M
est: 256.56M (+22.0%)
|
336.30M
est: 278.10M (+20.9%)
|
394.10M
est: 330.10M (+19.4%)
|
—
est: 347.85M (-100.0%)
|
456.20M
est: 362.67M (+25.8%)
|
367.55M
359.48M – 377.31M
+1.3% YoY
|
388.48M
375.83M – 398.86M
+5.7% YoY
|
407.37M
407.37M – 407.37M
+4.9% YoY
|
416.18M
404.77M – 427.26M
+2.2% YoY
|
| EPS |
0.02
est: 0.11 (-83.5%)
|
0.15
est: 0.18 (-17.6%)
|
0.13
est: 0.18 (-27.7%)
|
0.04
est: 0.15 (-71.6%)
|
0.00
est: 0.06 (-99.7%)
|
0.02
est: 0.05 (-65.5%)
|
-0.58
est: -0.10 (-507.0%)
|
-0.02
est: 0.00 (-34,671.4%)
|
0.02
est: 0.03 (-33.7%)
|
0.07
est: 0.07 (-3.6%)
|
0.06
est: 0.10 (-34.5%)
|
0.04
est: 0.09 (-53.8%)
|
0.08
0.06 – 0.10
-9.9% YoY
|
0.14
0.09 – 0.18
+68.8% YoY
|
0.16
0.15 – 0.17
+19.6% YoY
|
0.19
0.18 – 0.20
+17.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 2/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Amundi Prime UK Mid & Small Cap UCITS ETF DR - GBP (D) PRUK.L | 0.33% | 1.40M | 0.05% |
| 2 | Vanguard FTSE 250 UCITS ETF VMIG.MI | 0.19% | 5.14M | 0.10% |
| 3 | Vanguard FTSE 250 UCITS ETF (GBP) Distributing VMID.DE | 0.19% | 5.14M | 0.10% |
| 4 | Xtrackers FTSE 250 UCITS ETF 1D XMCX.L | 0.19% | 71.9K | 0.15% |
| 5 | Invesco FTSE 250 UCITS ETF S250.L | 0.19% | 66.3K | 0.12% |
| 6 | HSBC FTSE 250 UCITS ETF HMCX.L | 0.18% | 123.7K | 0.09% |
| 7 | iShares FTSE 250 UCITS ETF MIDD.L | 0.18% | 1.55M | 0.40% |
| 8 | iShares MSCI United Kingdom Small-Cap ETF EWUS | 0.17% | 66.7K | 0.59% |
| 9 | iShares MSCI UK Small Cap UCITS ETF CUKS.L | 0.16% | 208.2K | 0.58% |
| 10 | Dimensional - International Small Cap Value ETF DISV | 0.11% | 5.13M | 0.42% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Justinian Joseph Ash | Chief Executive Officer & Executive Director | 735.2K | male |
| Harbant Samra | Chief Financial Officer & Executive Director | 445.9K | male |
| Derrick Farrell | Chief Executive Officer of Vita Health Group | — | male |
| Amie Gramlick | Director of Commercial Finance & Investor Relations | — | female |
| Lisa Grant | Group Chief Nursing Officer & COO | — | — |
| Mantraraj Budhdev | Group General Counsel, Company Secretary & Chief People Officer | — | male |
| Peter Corfield | Chief Commercial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SPI.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
